PL3372607T3 - Postać krystaliczna inhibitora kinazy btk i sposób jego otrzymywania - Google Patents

Postać krystaliczna inhibitora kinazy btk i sposób jego otrzymywania

Info

Publication number
PL3372607T3
PL3372607T3 PL16883403T PL16883403T PL3372607T3 PL 3372607 T3 PL3372607 T3 PL 3372607T3 PL 16883403 T PL16883403 T PL 16883403T PL 16883403 T PL16883403 T PL 16883403T PL 3372607 T3 PL3372607 T3 PL 3372607T3
Authority
PL
Poland
Prior art keywords
preparation
crystalline form
kinase inhibitor
btk kinase
btk
Prior art date
Application number
PL16883403T
Other languages
English (en)
Inventor
Guaili Wu
Zhenjun QIU
Xi LU
Yun Lu
Original Assignee
Jiangsu Hengrui Medicine Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co. Ltd. filed Critical Jiangsu Hengrui Medicine Co. Ltd.
Publication of PL3372607T3 publication Critical patent/PL3372607T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL16883403T 2016-01-05 2016-12-20 Postać krystaliczna inhibitora kinazy btk i sposób jego otrzymywania PL3372607T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610006080 2016-01-05
PCT/CN2016/111051 WO2017118277A1 (zh) 2016-01-05 2016-12-20 一种btk激酶抑制剂的结晶形式及其制备方法
EP16883403.4A EP3372607B1 (en) 2016-01-05 2016-12-20 Crystalline form of btk kinase inhibitor and preparation method thereof

Publications (1)

Publication Number Publication Date
PL3372607T3 true PL3372607T3 (pl) 2021-09-20

Family

ID=59273271

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16883403T PL3372607T3 (pl) 2016-01-05 2016-12-20 Postać krystaliczna inhibitora kinazy btk i sposób jego otrzymywania

Country Status (15)

Country Link
US (1) US10626116B2 (pl)
EP (1) EP3372607B1 (pl)
JP (1) JP6913274B2 (pl)
KR (1) KR102688907B1 (pl)
CN (1) CN107406453B (pl)
AU (1) AU2016384921C1 (pl)
BR (1) BR112018012106B1 (pl)
CA (1) CA3009256C (pl)
ES (1) ES2875384T3 (pl)
HK (1) HK1243419B (pl)
MX (1) MX376500B (pl)
PL (1) PL3372607T3 (pl)
RU (1) RU2728827C2 (pl)
TW (1) TWI726030B (pl)
WO (1) WO2017118277A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602752B (zh) 2016-02-12 2021-07-02 阿克苏诺贝尔化学品国际有限公司 制备高级亚乙基胺和亚乙基胺衍生物的方法
KR20200144546A (ko) * 2018-04-13 2020-12-29 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피롤로아미노피리다지논 화합물 및 이의 중간체의 제조 방법
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
US20220362357A1 (en) 2018-08-31 2022-11-17 Stichting Radboud Universitair Medisch Centrum Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
CN111499642A (zh) * 2019-01-31 2020-08-07 江苏恒瑞医药股份有限公司 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
TW202100527A (zh) * 2019-05-31 2021-01-01 大陸商江蘇恆瑞醫藥股份有限公司 一種固體分散體及其製備方法
CN110372562B (zh) 2019-07-09 2021-04-06 上海再启生物技术有限公司 一种btk激酶抑制剂关键中间体的晶型及其制备方法
CN112745255A (zh) * 2019-10-30 2021-05-04 江苏恒瑞医药股份有限公司 一种btk激酶抑制剂的制备方法
KR20230050363A (ko) * 2020-08-10 2023-04-14 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질환의 치료에 있어서 btk 저해제의 용도
UY39377A (es) 2020-08-14 2022-03-31 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
WO2022104150A1 (en) 2020-11-12 2022-05-19 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
WO2022261138A1 (en) 2021-06-08 2022-12-15 Tg Therapeutics, Inc. Disrupted ikaros signaling as biomarker for btk inhibition
CN114751850B (zh) * 2022-06-06 2023-08-25 上海再启生物技术有限公司 一种btk激酶抑制剂关键中间体的制备方法
CN114989062A (zh) * 2022-07-04 2022-09-02 上海再启生物技术有限公司 一种btk激酶抑制剂中间体的晶型及其制备方法
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2026133229A1 (en) 2024-12-20 2026-06-25 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5271897B2 (ja) * 2006-05-31 2013-08-21 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ ポリ(ADP−リボース)ポリメラーゼ(PARP)の阻害剤としての、ピロロ[1,2−a]ピラジン−1(2H)−オン及びピロロ[1,2−d][1,2,4]トリアジン−1(2H)−オン誘導体
EP2139487B1 (en) * 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CN102711765A (zh) * 2009-11-16 2012-10-03 加利福尼亚大学董事会 激酶抑制剂
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
EP2890691B1 (en) * 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
KR102073797B1 (ko) * 2014-07-07 2020-02-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 단백질 키나제 저해제로서의 아미노피리다지논 화합물
EP3626239B1 (en) * 2017-05-18 2024-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ezh2 inhibitor combined with btk inhibitor for treating tumor

Also Published As

Publication number Publication date
EP3372607A4 (en) 2018-10-03
RU2728827C2 (ru) 2020-07-31
BR112018012106A2 (pt) 2018-12-04
CN107406453A (zh) 2017-11-28
MX376500B (es) 2025-03-07
KR102688907B1 (ko) 2024-07-29
EP3372607B1 (en) 2021-04-28
RU2018125277A3 (pl) 2020-02-28
CN107406453B (zh) 2018-12-28
CA3009256A1 (en) 2017-07-13
HK1243419B (zh) 2019-11-22
CA3009256C (en) 2023-08-22
TWI726030B (zh) 2021-05-01
JP6913274B2 (ja) 2021-08-04
AU2016384921C1 (en) 2021-05-20
US10626116B2 (en) 2020-04-21
BR112018012106B1 (pt) 2023-12-12
KR20180099787A (ko) 2018-09-05
MX2018008131A (es) 2018-09-03
JP2019500357A (ja) 2019-01-10
ES2875384T3 (es) 2021-11-10
US20190010161A1 (en) 2019-01-10
WO2017118277A1 (zh) 2017-07-13
TW201725207A (zh) 2017-07-16
RU2018125277A (ru) 2020-02-07
AU2016384921A1 (en) 2018-07-26
EP3372607A1 (en) 2018-09-12
AU2016384921B2 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
EP3372607A4 (en) Crystalline form of btk kinase inhibitor and preparation method thereof
HUE047404T2 (hu) JAK kináz inhibitor biszulfát kristályos alakja és eljárás elõállítására
IL255738A (en) A new crystalline form of lenbatinib mesylate and a process for its preparation
IL259801A (en) ezh2 inhibitors and methods of using them
SG10201509488YA (en) A Novel Crystalline Form Of A Benzimidazole Derivative And A Preparation Method Thereof
SG10201912302VA (en) Salts of pi3k inhibitor and processes for their preparation
IL257061A (en) Inhibitors of ezh2
EP3265093A4 (en) Tricyclic kinase inhibitors of melk and methods of use
HUE047626T2 (hu) Ciklin-függõ, fehérje kináz inhibitor hidroxietil-szulfonátja, annak kristályos formája és elõállítására szolgáló eljárás
IL251197A0 (en) The crystal forms of tyrosine kinase inhibitors and their salts
PL3327012T3 (pl) Krystaliczne postacie bilastyny i sposoby ich wytwarzania
SI3348546T1 (sl) Kristalinična oblika zaviralca androgenega receptorja in postopek priprave le-tega
GB201721201D0 (en) Process for preparing novel crystalline form of iodosulfuron-methyl-sodium and use
HK1261294A1 (en) Process for the preparation of kinase inhibitors and intermediates thereof
GB201510576D0 (en) Implants and methods of forming thereof